Distinct Patterns of Endothelin Axis Expression in Primary Prostate Cancer

Geeta Godara, Stefana Pecher, Drazen M. Jukic, Jason M. D'Antonio, Ardavan Akhavan, Joel B. Nelson, Beth Pflug

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives: Emerging evidence supports a role for endothelin-1 (ET-1), endothelin A and B receptors (ETA and ETB, respectively), and neutral endopeptidase (NEP) in the progression of prostate carcinoma. In clinical trials for advanced prostate cancer, ET axis blockade significantly delayed the time to disease progression in a subset of patients. We examined ET axis expression in prostate cancer, prostatic intraepithelial neoplasia, and normal adjacent tissue and then analyzed the relationship of the protein levels with disease progression. Methods: The expression levels of ETA, ETB, and NEP were determined in 120 prostate cancer specimens obtained at surgery or biopsy by immunohistochemistry. In situ hybridization on a subset of the specimens was used to confirm the immunohistochemistry findings. Results: In regions of adenocarcinoma, immunohistochemistry analysis demonstrated high ETA expression in 72% of the specimens. ETA expression was significantly elevated with increased pathologic stage and grade. ETB and NEP levels were significantly decreased in adenocarcinoma compared with normal adjacent tissue and prostatic intraepithelial neoplasia; however, reduced expression did not correlate with tumor grade or stage. Patients with prostate-specific antigen recurrence had significantly greater ETA levels in their primary tumors than did patients who were disease free 5 years after prostatectomy. Patients with high ETA expression in the adenocarcinoma regions with low ETB and NEP had a significantly decreased interval to prostate-specific antigen progression compared with patients with low ETA or high ETB/NEP expression. Conclusions: These data suggest two patterns of ETA expression in primary prostate cancer, with increased expression correlating with more advanced disease. The use of these expression patterns to identify patients more likely to respond to ET axis blockade might enhance treatment outcomes.

Original languageEnglish (US)
Pages (from-to)209-215
Number of pages7
JournalUrology
Volume70
Issue number1
DOIs
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

Endothelins
Neprilysin
Prostatic Neoplasms
Prostatic Intraepithelial Neoplasia
Adenocarcinoma
Immunohistochemistry
Prostate-Specific Antigen
Disease Progression
Endothelin B Receptors
Endothelin A Receptors
Endothelin-1
Prostatectomy
In Situ Hybridization
Prostate
Neoplasms
Clinical Trials
Carcinoma
Biopsy
Recurrence
Proteins

ASJC Scopus subject areas

  • Urology

Cite this

Godara, G., Pecher, S., Jukic, D. M., D'Antonio, J. M., Akhavan, A., Nelson, J. B., & Pflug, B. (2007). Distinct Patterns of Endothelin Axis Expression in Primary Prostate Cancer. Urology, 70(1), 209-215. https://doi.org/10.1016/j.urology.2007.03.017

Distinct Patterns of Endothelin Axis Expression in Primary Prostate Cancer. / Godara, Geeta; Pecher, Stefana; Jukic, Drazen M.; D'Antonio, Jason M.; Akhavan, Ardavan; Nelson, Joel B.; Pflug, Beth.

In: Urology, Vol. 70, No. 1, 07.2007, p. 209-215.

Research output: Contribution to journalArticle

Godara, G, Pecher, S, Jukic, DM, D'Antonio, JM, Akhavan, A, Nelson, JB & Pflug, B 2007, 'Distinct Patterns of Endothelin Axis Expression in Primary Prostate Cancer', Urology, vol. 70, no. 1, pp. 209-215. https://doi.org/10.1016/j.urology.2007.03.017
Godara G, Pecher S, Jukic DM, D'Antonio JM, Akhavan A, Nelson JB et al. Distinct Patterns of Endothelin Axis Expression in Primary Prostate Cancer. Urology. 2007 Jul;70(1):209-215. https://doi.org/10.1016/j.urology.2007.03.017
Godara, Geeta ; Pecher, Stefana ; Jukic, Drazen M. ; D'Antonio, Jason M. ; Akhavan, Ardavan ; Nelson, Joel B. ; Pflug, Beth. / Distinct Patterns of Endothelin Axis Expression in Primary Prostate Cancer. In: Urology. 2007 ; Vol. 70, No. 1. pp. 209-215.
@article{19691d446a924d25a0f10a783a5cc5b4,
title = "Distinct Patterns of Endothelin Axis Expression in Primary Prostate Cancer",
abstract = "Objectives: Emerging evidence supports a role for endothelin-1 (ET-1), endothelin A and B receptors (ETA and ETB, respectively), and neutral endopeptidase (NEP) in the progression of prostate carcinoma. In clinical trials for advanced prostate cancer, ET axis blockade significantly delayed the time to disease progression in a subset of patients. We examined ET axis expression in prostate cancer, prostatic intraepithelial neoplasia, and normal adjacent tissue and then analyzed the relationship of the protein levels with disease progression. Methods: The expression levels of ETA, ETB, and NEP were determined in 120 prostate cancer specimens obtained at surgery or biopsy by immunohistochemistry. In situ hybridization on a subset of the specimens was used to confirm the immunohistochemistry findings. Results: In regions of adenocarcinoma, immunohistochemistry analysis demonstrated high ETA expression in 72{\%} of the specimens. ETA expression was significantly elevated with increased pathologic stage and grade. ETB and NEP levels were significantly decreased in adenocarcinoma compared with normal adjacent tissue and prostatic intraepithelial neoplasia; however, reduced expression did not correlate with tumor grade or stage. Patients with prostate-specific antigen recurrence had significantly greater ETA levels in their primary tumors than did patients who were disease free 5 years after prostatectomy. Patients with high ETA expression in the adenocarcinoma regions with low ETB and NEP had a significantly decreased interval to prostate-specific antigen progression compared with patients with low ETA or high ETB/NEP expression. Conclusions: These data suggest two patterns of ETA expression in primary prostate cancer, with increased expression correlating with more advanced disease. The use of these expression patterns to identify patients more likely to respond to ET axis blockade might enhance treatment outcomes.",
author = "Geeta Godara and Stefana Pecher and Jukic, {Drazen M.} and D'Antonio, {Jason M.} and Ardavan Akhavan and Nelson, {Joel B.} and Beth Pflug",
year = "2007",
month = "7",
doi = "10.1016/j.urology.2007.03.017",
language = "English (US)",
volume = "70",
pages = "209--215",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Distinct Patterns of Endothelin Axis Expression in Primary Prostate Cancer

AU - Godara, Geeta

AU - Pecher, Stefana

AU - Jukic, Drazen M.

AU - D'Antonio, Jason M.

AU - Akhavan, Ardavan

AU - Nelson, Joel B.

AU - Pflug, Beth

PY - 2007/7

Y1 - 2007/7

N2 - Objectives: Emerging evidence supports a role for endothelin-1 (ET-1), endothelin A and B receptors (ETA and ETB, respectively), and neutral endopeptidase (NEP) in the progression of prostate carcinoma. In clinical trials for advanced prostate cancer, ET axis blockade significantly delayed the time to disease progression in a subset of patients. We examined ET axis expression in prostate cancer, prostatic intraepithelial neoplasia, and normal adjacent tissue and then analyzed the relationship of the protein levels with disease progression. Methods: The expression levels of ETA, ETB, and NEP were determined in 120 prostate cancer specimens obtained at surgery or biopsy by immunohistochemistry. In situ hybridization on a subset of the specimens was used to confirm the immunohistochemistry findings. Results: In regions of adenocarcinoma, immunohistochemistry analysis demonstrated high ETA expression in 72% of the specimens. ETA expression was significantly elevated with increased pathologic stage and grade. ETB and NEP levels were significantly decreased in adenocarcinoma compared with normal adjacent tissue and prostatic intraepithelial neoplasia; however, reduced expression did not correlate with tumor grade or stage. Patients with prostate-specific antigen recurrence had significantly greater ETA levels in their primary tumors than did patients who were disease free 5 years after prostatectomy. Patients with high ETA expression in the adenocarcinoma regions with low ETB and NEP had a significantly decreased interval to prostate-specific antigen progression compared with patients with low ETA or high ETB/NEP expression. Conclusions: These data suggest two patterns of ETA expression in primary prostate cancer, with increased expression correlating with more advanced disease. The use of these expression patterns to identify patients more likely to respond to ET axis blockade might enhance treatment outcomes.

AB - Objectives: Emerging evidence supports a role for endothelin-1 (ET-1), endothelin A and B receptors (ETA and ETB, respectively), and neutral endopeptidase (NEP) in the progression of prostate carcinoma. In clinical trials for advanced prostate cancer, ET axis blockade significantly delayed the time to disease progression in a subset of patients. We examined ET axis expression in prostate cancer, prostatic intraepithelial neoplasia, and normal adjacent tissue and then analyzed the relationship of the protein levels with disease progression. Methods: The expression levels of ETA, ETB, and NEP were determined in 120 prostate cancer specimens obtained at surgery or biopsy by immunohistochemistry. In situ hybridization on a subset of the specimens was used to confirm the immunohistochemistry findings. Results: In regions of adenocarcinoma, immunohistochemistry analysis demonstrated high ETA expression in 72% of the specimens. ETA expression was significantly elevated with increased pathologic stage and grade. ETB and NEP levels were significantly decreased in adenocarcinoma compared with normal adjacent tissue and prostatic intraepithelial neoplasia; however, reduced expression did not correlate with tumor grade or stage. Patients with prostate-specific antigen recurrence had significantly greater ETA levels in their primary tumors than did patients who were disease free 5 years after prostatectomy. Patients with high ETA expression in the adenocarcinoma regions with low ETB and NEP had a significantly decreased interval to prostate-specific antigen progression compared with patients with low ETA or high ETB/NEP expression. Conclusions: These data suggest two patterns of ETA expression in primary prostate cancer, with increased expression correlating with more advanced disease. The use of these expression patterns to identify patients more likely to respond to ET axis blockade might enhance treatment outcomes.

UR - http://www.scopus.com/inward/record.url?scp=34447513701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447513701&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2007.03.017

DO - 10.1016/j.urology.2007.03.017

M3 - Article

VL - 70

SP - 209

EP - 215

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -